TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma

Detalles Bibliográficos
Autores principales: Xu, Caihua, Li, Dapeng, Duan, Weiming, Tao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474410/
https://www.ncbi.nlm.nih.gov/pubmed/34589932
http://dx.doi.org/10.1016/j.jtocrr.2020.100034
_version_ 1784575213830144000
author Xu, Caihua
Li, Dapeng
Duan, Weiming
Tao, Min
author_facet Xu, Caihua
Li, Dapeng
Duan, Weiming
Tao, Min
author_sort Xu, Caihua
collection PubMed
description
format Online
Article
Text
id pubmed-8474410
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84744102021-09-28 TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma Xu, Caihua Li, Dapeng Duan, Weiming Tao, Min JTO Clin Res Rep Case Report Elsevier 2020-03-14 /pmc/articles/PMC8474410/ /pubmed/34589932 http://dx.doi.org/10.1016/j.jtocrr.2020.100034 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Xu, Caihua
Li, Dapeng
Duan, Weiming
Tao, Min
TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
title TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
title_full TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
title_fullStr TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
title_full_unstemmed TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
title_short TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
title_sort tpd52l1-ros1 rearrangement as a new acquired resistance mechanism to osimertinib that responds to crizotinib in combination with osimertinib in lung adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474410/
https://www.ncbi.nlm.nih.gov/pubmed/34589932
http://dx.doi.org/10.1016/j.jtocrr.2020.100034
work_keys_str_mv AT xucaihua tpd52l1ros1rearrangementasanewacquiredresistancemechanismtoosimertinibthatrespondstocrizotinibincombinationwithosimertinibinlungadenocarcinoma
AT lidapeng tpd52l1ros1rearrangementasanewacquiredresistancemechanismtoosimertinibthatrespondstocrizotinibincombinationwithosimertinibinlungadenocarcinoma
AT duanweiming tpd52l1ros1rearrangementasanewacquiredresistancemechanismtoosimertinibthatrespondstocrizotinibincombinationwithosimertinibinlungadenocarcinoma
AT taomin tpd52l1ros1rearrangementasanewacquiredresistancemechanismtoosimertinibthatrespondstocrizotinibincombinationwithosimertinibinlungadenocarcinoma

Ejemplares similares